アルツハイマー病治療薬の世界市場予測および分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 15
1.2 List of Figures 21
2 Introduction 24
2.1 Catalyst 24
2.2 Related Reports 25
2.3 Upcoming Related Reports 25
3 Disease Overview 26
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 27
3.1.2 Pathophysiology 29
3.2 Disease Staging Systems 38
3.3 Symptoms 41
3.4 Prognosis 43
3.5 Quality of Life 43
4 Epidemiology 45
4.1 Disease Background 45
4.2 Risk Factors and Comorbidities 46
4.2.1 A family history of Alzheimer’s increases the risk of developing the disease by 7.5 times 47
4.2.2 The APOE ε4 allele triples the risk for AD 48
4.2.3 Cardiovascular risk factors in midlife significantly increase the risk of developing AD in later life 48
4.2.4 The incidence and prevalence of AD double every five years after age 65 years 49
4.2.5 Diabetes doubles the risk of AD in men, but only marginally affects the risk in women 49
4.2.6 Women are 1.5 times more likely to develop AD than men 50
4.2.7 Depression triples the risk for AD, and is the most common comorbidity 50
4.2.8 Up to 70% of AD patients also suffer from anxiety 51
4.2.9 Psychosis and agitation are common comorbidities in Alzheimer’s patients 51
4.3 Global Trends 51
4.3.1 US 52
4.3.2 5EU 53
4.3.3 Japan 55
4.3.4 China 56
4.3.5 India 56
4.4 Forecast Methodology 57
4.4.1 Sources Used 62
4.4.2 Forecast Assumptions and Methods 69
4.4.3 Sources Not Used 79
4.5 Epidemiology Forecast (2013-2023) 81
4.5.1 Total Prevalent Cases of AD 81
4.5.2 Age-Specific Total Prevalent Cases of AD 83
4.5.3 Sex-Specific Total Prevalent Cases of AD 85
4.5.4 Age-Standardized Total Prevalence of AD 88
4.5.5 Total Prevalent Cases of AD, by Severity 89
4.5.6 Total Prevalent Cases of MCI 91
4.5.7 Age-Specific Total Prevalent Cases of MCI 93
4.5.8 Sex-Specific Total Prevalent Cases of MCI 95
4.5.9 Age-Standardized Total Prevalence of MCI 98
4.6 Discussion 99
4.6.1 Conclusions Regarding the Epidemiological Trends 99
4.6.2 Limitations of the Analysis 101
4.6.3 Strengths of the Analysis 102
5 Disease Management 103
5.1 Diagnosis Overview 103
5.1.1 Probable AD Dementia 106
5.1.2 Preclinical AD 107
5.1.3 MCI 108
5.2 Treatment Overview 110
5.3 Clinical Practice 112
5.3.1 Leading Prescribed Therapies 114
5.4 US 115
5.5 France 118
5.6 Germany 120
5.7 Italy 122
5.8 Spain 124
5.9 UK 126
5.10 Japan 129
5.11 China 131
5.12 India 133
6 Competitive Assessment 135
6.1 Overview 135
6.2 Product Profiles – Major Brands 136
6.2.1 Aricept (donepezil hydrochloride) 136
6.2.2 Exelon (rivastigmine, rivastigmine tartrate) 141
6.2.3 Razadyne (galantamine hydrobromide) 146
6.2.4 Namenda (memantine hydrochloride) 151
6.3 Other Drugs/Classes 157
7 Unmet Need and Opportunity 159
7.1 Overview 159
7.2 Drugs with Disease-Modifying Mechanisms of Action 160
7.2.1 Unmet Need 160
7.2.2 Gap Analysis 161
7.2.3 Opportunity 162
7.3 Diagnosis in the Prodromal or Presymptomatic Stages 163
7.3.1 Unmet Need 163
7.3.2 Gap Analysis 164
7.3.3 Opportunity 165
7.4 Improved Control of Symptoms 166
7.4.1 Unmet Need 166
7.4.2 Gap Analysis 167
7.4.3 Opportunity 168
7.5 Easier Access to Treatment 169
7.5.1 Unmet Need 169
7.5.2 Gap Analysis 169
7.5.3 Opportunity 170
8 Pipeline Assessment 172
8.1 Overview 172
8.2 Clinical Trial Mapping 173
8.2.1 Clinical Trials by Class 173
8.3 Promising Drugs in Clinical Development 174
8.3.1 Biopharmaceutical Products 176
8.3.2 Small Molecule 209
8.3.3 Other Drugs in Development 258
9 Current and Future Players 260
9.1 Overview 260
9.2 Trends in Corporate Strategy 261
9.3 Company Profiles 262
9.3.1 Actavis 262
9.3.2 Lundbeck 265
9.3.3 Eisai 268
9.3.4 Pfizer 270
9.3.5 Novartis 272
9.3.6 Roche 274
9.3.7 Eli Lilly 276
9.3.8 Merck & Co. 280
9.3.9 AstraZeneca 281
9.3.10 Takeda 283
10 Market Outlook 286
10.1 Global Markets 286
10.1.1 Forecast 286
10.1.2 Drivers and Barriers – Global Issues 294
10.2 United States 297
10.2.1 Forecast 297
10.2.2 Key Events 301
10.2.3 Drivers and Barriers 302
10.3 France 305
10.3.1 Forecast 305
10.3.2 Key Events 308
10.3.3 Drivers and Barriers 309
10.4 Germany 312
10.4.1 Forecast 312
10.4.2 Key Events 315
10.4.3 Drivers and Barriers 315
10.5 Italy 317
10.5.1 Forecast 317
10.5.2 Key Events 321
10.5.3 Drivers and Barriers 321
10.6 Spain 323
10.6.1 Forecast 323
10.6.2 Key Events 327
10.6.3 Drivers and Barriers 327
10.7 United Kingdom 329
10.7.1 Forecast 329
10.7.2 Key Events 332
10.7.3 Drivers and Barriers 333
10.8 Japan 335
10.8.1 Forecast 335
10.8.2 Key Events 339
10.8.3 Drivers and Barriers 339
10.9 China 341
10.9.1 Forecast 341
10.9.2 Key Events 345
10.9.3 Drivers and Barriers 345
10.10 India 347
10.10.1 Forecast 347
10.10.2 Key Events 350
10.10.3 Drivers and Barriers 350
11 Appendix 353
11.1 Bibliography 353
11.2 Abbreviations 378
11.3 Methodology 388
11.4 Forecasting Methodology 388
11.4.1 Diagnosed AD Patients 388
11.4.2 Percent Drug-Treated Patients 389
11.4.3 Drugs Included in Each Therapeutic Class 389
11.4.4 Launch and Patent Expiry Dates 390
11.4.5 General Pricing Assumptions 391
11.4.6 Compliance Assumptions 392
11.4.7 Individual Drug Assumptions 394
11.4.8 Generic Erosion 400
11.4.9 Pricing of Pipeline Agents 400
11.5 Primary Research – KOLs Interviewed for This Report 402
11.6 Primary Research – Prescriber Survey 403
11.7 About the Authors 404
11.7.1 Analyst 404
11.7.2 Therapy Area Director 404
11.7.3 Epidemiologist 405
11.7.4 Global Head of Healthcare 405
11.8 About GlobalData 406
11.9 Disclaimer 406